Description
Embolization Particle Market Analysis
Market Overview
A non-invasive therapy known as embolisation, the Endovascular Particle is a cutting-edge concept that intends to halt not only hemorrhage but also ways to stop blood circulation to a tumour in a logical order to diminish it or in readiness for total abolition. Few embolised particles or tiny materials are forcefully injected into the clinic’s patients’ critical veins during the advanced process known as embolisation particle in order to entirely block or stop the blood flow to conventional cancerous cells.
A very small percentage of individuals who have pre-existing tumours that current surgery cannot entirely remove have the option of embolisation. Tumors that are too large to be cured with current ablation techniques can be treated with embolisation particles. Ablation can also use embolisation particles.
Embolization does, without a doubt, limit some of the blood flow to the healthy liver tissue that is present inside the body, thus it might not be a good alternative for some people whose livers have been damaged by diseases like serious hepatitis- or cirrhosis-related disorders. A significant part of contemporary interventional radiology uses embolisation particles in a variety of treatments.
Segment Overview
Insights into various market segments, including Structure, Application, and Region, can be found in the global embolisation particle market. The degree of occlusion, contemporary application, end-user, and numerous product kinds are used to segment the global market.
Research organisations, traders, importers, exporters, suppliers, and industry end users are the main market participants. The idea is picking up steam. The businesses are concentrating more on enhancing their methods for product innovation.
Many embolisation particle markets are being broken down and researched regionally, including those in Europe, Asia Pacific, North America, and the rest of the world.
Regional Analysis
Without a question, North America is the market leader because to the significant presence of international competitors in this area and the rapid improvement of technology. Geography predicts that North America will account for the largest share of profits owing to the increased use of various cloud-based services by means of manufacturing systems and various distribution channels. In addition, the market for the Asia Pacific region is expected to expand quickly due to increased investment.
Major Players
Market industry participants include: Medtronics, GuerbetTerumoBTG International Ltd. Sirtex, Boston Scientific Corporation, and Merit Medical.
COVID 19 Impacts
The market analysis for embolisation particles and 215 other nations have both been impacted by COVID 19. Countries have implemented lockdowns to address the harmful consequences, which has hurt the market for embolisation particles. The epidemic presents the industry with a number of difficulties because it has an international impact.
Many elements, including supply chain risk, distribution issues, a lack of workforce workers, and drastically reduced development activities, have had a major impact on current demand and supply. Consumers are not as engaged as they once were. There are significant strategic developments going on. Due to the rising demand from customers all over the world, MNCs are spending more in the market for embolisation particles.
TABLE OF CONTENTS
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 DEFINITION 15
2.2 SCOPE OF THE STUDY 15
2.2.1 RESEARCH OBJECTIVE 15
2.2.2 ASSUMPTIONS 15
2.2.3 LIMITATIONS 16
3 RESEARCH METHODOLOGY
3.1 PRIMARY RESEARCH METHODOLOGY 18
3.2 SECONDARY RESEARCH METHODOLOGY 19
3.3 MARKET SIZE ESTIMATION 20
3.4 MARKET SHARE ANALYSIS 22
3.5 TRADE ANALYSIS 22
3.6 MARKET PRICING APPROACH 22
4 MARKET DYNAMICS
4.1 INTRODUCTION 23
4.2 DRIVER 24
4.2.1 GROWING DEMAND OF EMBOLIZATION PARTICLES FOR INTERVENTIONAL RADIOLOGY AND INTERVENTIONAL CARDIOVASCULAR PROCEDURE (IMPACT WEIGHTAGE- 35%) 24
4.2.2 EMBOLIZATION IS BEST MINIMALLY INVASIVE ALTERNATIVES AVAILABLE FOR THE
INTERVENTIONAL PROCEDURES (IMPACT WEIGHTAGE- 30%) 25
4.2.3 INCREASING PREVALENCE OF VARIOUS TYPES OF CANCER IS ONE OF THE MAJOR FACTOR RESPONSIBLE FOR MARKET GROWTH (IMPACT WEIGHTAGE- 25%) 26
4.2.4 FAVOURABLE REIMBURSEMENT SCENARIO (IMPACT WEIGHTAGE- 10%) 27
4.3 RESTRAINTS 28
4.3.1 LESS NUMBER OF INTERVENTIONAL NEURORADIOLOGISTS AND INTERVENTIONAL
NEURORADIOLOGY (INR) LABS (IMPACT WEIGHTAGE- 40%) 28
4.3.2 STRICT REGULATORY RULES (IMPACT WEIGHTAGE-60% 29
4.4 OPPORTUNITIES 30
4.4.1 RECENT ADVANCES IN MICROSPHERE TECHNOLOGIES 30
4.5 MEGA TRENDS 30
4.6 MACROECONOMIC INDICATORS 31
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S 5 FORCES ANALYSIS 32
5.1.1 BARGAINING POWER OF SUPPLIERS 33
5.1.2 BARGAINING POWER OF BUYERS 33
5.1.3 THREAT OF NEW ENTRANTS 33
5.1.4 THREAT OF SUBSTITUTES 33
5.1.5 INTENSITY OF RIVALRY 33
5.2 VALUE CHAIN ANALYSIS 34
5.2.1 R&D 34
5.2.2 CLINICAL TEST & LEGAL ISSUES 35
5.2.3 MANUFACTURING 35
5.2.4 MARKETING & SALES 35
5.3 PURCHASING ACTIVITIES, STRATEGIES AND IMPLICATIONS 36
5.4 INVESTMENT OPPORTUNITY ANALYSIS 36
5.5 PRICING IMPACT OF EMBOLIZATION PARTICLE (LIPIODOL): EFFECTS & IMPLICATIONS 37
5.6 REIMBURSEMENT ISSUES IN EMBOLIZATION PROCEDURES 38
6 GLOBAL EMBOLIZATION PARTICLE MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION 40
6.2 RADIOEMBOLIZATION SPHERES 41
6.3 DRUG ELUTING BEADS 42
7 GLOBAL EMBOLIZATION PARTICLE MARKET, BY APPLICATION
7.1 INTRODUCTION 43
7.2 ONCOLOGY 45
7.3 UROLOGY 46
7.4 PERIPHERAL VASCULAR DISEASE 47
7.5 NEUROLOGY 48
8 GLOBAL EMBOLIZATION PARTICLE MARKET, BY LEVEL OF OCCLUSION
8.1 INTRODUCTION 49
8.1.1 PROXIMAL 50
8.1.2 DISTAL 50
9 GLOBAL EMBOLIZATION PARTICLE MARKET, BY END USER
9.1 INTRODUCTION 51
9.2 HOSPITALS & CLINICS 52
9.3 AMBULATORY CENTERS 53
10 GLOBAL EMBOLIZATION PARTICLE MARKET, BY REGION
10.1 INTRODUCTION 54
10.2 AMERICAS 56
10.2.1 U.S. 59
10.2.2 CANADA 61
10.2.3 SOUTH AMERICA 63
10.3 EUROPE 66
10.3.1 GERMANY 69
10.3.2 FRANCE 71
10.3.3 UK 73
10.3.4 ITALY 75
10.3.5 SPAIN 77
10.3.6 REST OF EUROPE 79
10.4 ASIA PACIFIC 82
10.4.1 JAPAN 85
10.4.2 CHINA 87
10.4.3 INDIA 89
10.4.4 REPUBLIC OF KOREA 91
10.4.5 AUSTRALIA 93
10.4.6 REST OF ASIA PACIFIC 95
10.4.7 MIDDLE EAST & AFRICA 97
11 COMPETITIVE LANDSCAPE
11.1 INTRODUCTION 100
11.2 COMPANY SHARE ANALYSIS 101
12 COMPANY PROFILES
12.1 BOSTON SCIENTIFIC CORPORATION 102
12.1.1 COMPANY OVERVIEW 102
12.1.2 FINANCIALS 102
12.1.3 PRODUCTS 102
12.1.4 STRATEGY 102
12.1.5 KEY DEVELOPMENTS 102
12.2 GUERBET 103
12.2.1 COMPANY OVERVIEW 103
12.2.2 FINANCIALS 103
12.2.3 PRODUCTS 103
12.2.4 STRATEGY 103
12.2.5 KEY DEVELOPMENTS 103
12.3 BTG INTERNATIONAL LTD 104
12.3.1 COMPANY OVERVIEW 104
12.3.2 FINANCIALS 104
12.3.3 PRODUCTS 104
12.3.4 STRATEGY 104
12.3.5 KEY DEVELOPMENTS 104
12.4 MEDTRONICS 105
12.4.1 COMPANY OVERVIEW 105
12.4.2 FINANCIALS 105
12.4.3 PRODUCTS 105
12.4.4 STRATEGY 105
12.4.5 KEY DEVELOPMENTS 105
12.5 SIRTEX 106
12.5.1 COMPANY OVERVIEW 106
12.5.2 FINANCIALS 106
12.5.3 PRODUCTS 106
12.5.4 STRATEGY 106
12.5.5 KEY DEVELOPMENTS 106
12.6 TERUMO 107
12.6.1 COMPANY OVERVIEW 107
12.6.2 FINANCIALS 107
12.6.3 PRODUCTS 107
12.6.4 STRATEGY 107
12.6.5 KEY DEVELOPMENTS 107
12.7 MERIT MEDICAL 108
12.7.1 COMPANY OVERVIEW 108
12.7.2 FINANCIALS 108
12.7.3 PRODUCTS 108
12.7.4 STRATEGY 108
12.7.5 KEY DEVELOPMENTS 108
13 MRFR CONCLUSION
13.1 KEY FINDINGS 109
13.1.1 FROM CEO’S VIEW POINT 109
13.1.2 UNMET NEEDS 109
13.2 KEY COMPANIES TO WATCH 109
14 APPENDIX
14.1 DISCUSSION BLUE PRINT 110
14.2 REFERENCES 112
